.Pharmacolibrary.Drugs.ATC.J.J06BD02 .Pharmacolibrary.Drugs.ATC.J.J06BD02| name: | Motavizumab |
| ATC code: | J06BD02 | route: | intravenous |
| n-compartments | 2 |
Motavizumab is a humanized monoclonal antibody that targets the fusion (F) protein of respiratory syncytial virus (RSV). It was developed for the prevention of RSV infection in high-risk infants and children; however, motavizumab is not currently approved for use due to regulatory concerns and insufficient demonstration of clinical benefit over palivizumab.
Pharmacokinetic parameters estimated for typical healthy pediatric patients based on reported data for IgG monoclonal antibodies of similar type, as there are no peer-reviewed, published PK parameters specifically for motavizumab.